Derma Sciences, Inc. (NASDAQ: DSCI) Stock Competitors & Peer Comparison
See DSCI's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Equipment & Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for DSCI and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DSCI | $7.00 | +0.00% | 0 | -0.02 | -$347.22 | N/A |
| SIRO | $109.97 | +0.00% | 22B | 31.88 | $3.45 | N/A |
| HIMS | $31.59 | +6.51% | 7B | -315.90 | -$0.10 | N/A |
| MMED | $19.60 | +6.41% | 5.5B | -25.29 | -$0.78 | N/A |
| OMCL | $36.81 | +1.80% | 1.7B | 19.27 | $1.91 | N/A |
| DRTS | $13.14 | +1.15% | 1.2B | -19.61 | -$0.67 | N/A |
| MLAB | $102.65 | +1.62% | 574.4M | 10.36 | $9.91 | +0.62% |
| LAB | $0.80 | -0.01% | 313.2M | -11.43 | -$0.07 | N/A |
| STXS | $1.42 | +4.41% | 139M | -8.35 | -$0.17 | N/A |
| FONR | $19.09 | +0.00% | 117.8M | 19.09 | $1.00 | N/A |
Stock Comparison
Sirona Dental Systems, Inc. (NASDAQ: SIRO)
DSCI vs SIRO Comparison August 2026
Derma Sciences, Inc. (NASDAQ: DSCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DSCI stands at 0. In comparison, SIRO has a market cap of 22B. Regarding current trading prices, DSCI is priced at $7.00 on the NASDAQ, while SIRO trades at $109.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DSCI currently has a P/E ratio of -0.02, whereas SIRO's P/E ratio is 31.88. In terms of profitability, DSCI's ROE is -0.00%, compared to SIRO's ROE of +0.14%. Regarding short-term risk, DSCI is less volatile compared to SIRO. This indicates lower risk in terms of short-term price fluctuations for DSCI.Check SIRO's competition here
Hims & Hers Health, Inc. (NYSE: HIMS)
DSCI vs HIMS Comparison August 2026
Derma Sciences, Inc. (NASDAQ: DSCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DSCI stands at 0. In comparison, HIMS has a market cap of 7B. Regarding current trading prices, DSCI is priced at $7.00 on the NASDAQ, while HIMS trades at $31.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DSCI currently has a P/E ratio of -0.02, whereas HIMS's P/E ratio is -315.90. In terms of profitability, DSCI's ROE is -0.00%, compared to HIMS's ROE of -0.02%. Regarding short-term risk, DSCI is less volatile compared to HIMS. This indicates lower risk in terms of short-term price fluctuations for DSCI.Check HIMS's competition here
MiniMed Group, Inc. Common Stock (NASDAQ: MMED)
DSCI vs MMED Comparison August 2026
Derma Sciences, Inc. (NASDAQ: DSCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DSCI stands at 0. In comparison, MMED has a market cap of 5.5B. Regarding current trading prices, DSCI is priced at $7.00 on the NASDAQ, while MMED trades at $19.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DSCI currently has a P/E ratio of -0.02, whereas MMED's P/E ratio is -25.29. In terms of profitability, DSCI's ROE is -0.00%, compared to MMED's ROE of -0.14%. Regarding short-term risk, DSCI is less volatile compared to MMED. This indicates lower risk in terms of short-term price fluctuations for DSCI.Check MMED's competition here
Omnicell, Inc. (NASDAQ: OMCL)
DSCI vs OMCL Comparison August 2026
Derma Sciences, Inc. (NASDAQ: DSCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DSCI stands at 0. In comparison, OMCL has a market cap of 1.7B. Regarding current trading prices, DSCI is priced at $7.00 on the NASDAQ, while OMCL trades at $36.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DSCI currently has a P/E ratio of -0.02, whereas OMCL's P/E ratio is 19.27. In terms of profitability, DSCI's ROE is -0.00%, compared to OMCL's ROE of +0.03%. Regarding short-term risk, DSCI is less volatile compared to OMCL. This indicates lower risk in terms of short-term price fluctuations for DSCI.Check OMCL's competition here
Alpha Tau Medical Ltd (NASDAQ: DRTS)
DSCI vs DRTS Comparison August 2026
Derma Sciences, Inc. (NASDAQ: DSCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DSCI stands at 0. In comparison, DRTS has a market cap of 1.2B. Regarding current trading prices, DSCI is priced at $7.00 on the NASDAQ, while DRTS trades at $13.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DSCI currently has a P/E ratio of -0.02, whereas DRTS's P/E ratio is -19.61. In terms of profitability, DSCI's ROE is -0.00%, compared to DRTS's ROE of -0.73%. Regarding short-term risk, DSCI is less volatile compared to DRTS. This indicates lower risk in terms of short-term price fluctuations for DSCI.Check DRTS's competition here
Mesa Laboratories, Inc. (NASDAQ: MLAB)
DSCI vs MLAB Comparison August 2026
Derma Sciences, Inc. (NASDAQ: DSCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DSCI stands at 0. In comparison, MLAB has a market cap of 574.4M. Regarding current trading prices, DSCI is priced at $7.00 on the NASDAQ, while MLAB trades at $102.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DSCI currently has a P/E ratio of -0.02, whereas MLAB's P/E ratio is 10.36. In terms of profitability, DSCI's ROE is -0.00%, compared to MLAB's ROE of +0.04%. Regarding short-term risk, DSCI is less volatile compared to MLAB. This indicates lower risk in terms of short-term price fluctuations for DSCI.Check MLAB's competition here
Standard BioTools Inc. (NASDAQ: LAB)
DSCI vs LAB Comparison August 2026
Derma Sciences, Inc. (NASDAQ: DSCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DSCI stands at 0. In comparison, LAB has a market cap of 313.2M. Regarding current trading prices, DSCI is priced at $7.00 on the NASDAQ, while LAB trades at $0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DSCI currently has a P/E ratio of -0.02, whereas LAB's P/E ratio is -11.43. In terms of profitability, DSCI's ROE is -0.00%, compared to LAB's ROE of -0.18%. Regarding short-term risk, DSCI is less volatile compared to LAB. This indicates lower risk in terms of short-term price fluctuations for DSCI.Check LAB's competition here
Stereotaxis, Inc. (AMEX: STXS)
DSCI vs STXS Comparison August 2026
Derma Sciences, Inc. (NASDAQ: DSCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DSCI stands at 0. In comparison, STXS has a market cap of 139M. Regarding current trading prices, DSCI is priced at $7.00 on the NASDAQ, while STXS trades at $1.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DSCI currently has a P/E ratio of -0.02, whereas STXS's P/E ratio is -8.35. In terms of profitability, DSCI's ROE is -0.00%, compared to STXS's ROE of -1.53%. Regarding short-term risk, DSCI is less volatile compared to STXS. This indicates lower risk in terms of short-term price fluctuations for DSCI.Check STXS's competition here
Fonar Corp. (NASDAQ: FONR)
DSCI vs FONR Comparison August 2026
Derma Sciences, Inc. (NASDAQ: DSCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DSCI stands at 0. In comparison, FONR has a market cap of 117.8M. Regarding current trading prices, DSCI is priced at $7.00 on the NASDAQ, while FONR trades at $19.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DSCI currently has a P/E ratio of -0.02, whereas FONR's P/E ratio is 19.09. In terms of profitability, DSCI's ROE is -0.00%, compared to FONR's ROE of +0.04%. Regarding short-term risk, DSCI is more volatile compared to FONR. This indicates higher risk in terms of short-term price fluctuations for DSCI.Check FONR's competition here
LENSAR Inc (NASDAQ: LNSR)
DSCI vs LNSR Comparison August 2026
Derma Sciences, Inc. (NASDAQ: DSCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DSCI stands at 0. In comparison, LNSR has a market cap of 74.2M. Regarding current trading prices, DSCI is priced at $7.00 on the NASDAQ, while LNSR trades at $6.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DSCI currently has a P/E ratio of -0.02, whereas LNSR's P/E ratio is 6.16. In terms of profitability, DSCI's ROE is -0.00%, compared to LNSR's ROE of -5.15%. Regarding short-term risk, DSCI is less volatile compared to LNSR. This indicates lower risk in terms of short-term price fluctuations for DSCI.Check LNSR's competition here
Kindly MD, Inc. (NASDAQ: KDLY)
DSCI vs KDLY Comparison August 2026
Derma Sciences, Inc. (NASDAQ: DSCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DSCI stands at 0. In comparison, KDLY has a market cap of 68.1M. Regarding current trading prices, DSCI is priced at $7.00 on the NASDAQ, while KDLY trades at $11.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DSCI currently has a P/E ratio of -0.02, whereas KDLY's P/E ratio is -15.48. In terms of profitability, DSCI's ROE is -0.00%, compared to KDLY's ROE of -0.85%. Regarding short-term risk, DSCI is less volatile compared to KDLY. This indicates lower risk in terms of short-term price fluctuations for DSCI.Check KDLY's competition here
NeueHealth, Inc. (NYSE: NEUE)
DSCI vs NEUE Comparison August 2026
Derma Sciences, Inc. (NASDAQ: DSCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DSCI stands at 0. In comparison, NEUE has a market cap of 60.9M. Regarding current trading prices, DSCI is priced at $7.00 on the NASDAQ, while NEUE trades at $6.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DSCI currently has a P/E ratio of -0.02, whereas NEUE's P/E ratio is -0.38. In terms of profitability, DSCI's ROE is -0.00%, compared to NEUE's ROE of +0.05%. Regarding short-term risk, DSCI is less volatile compared to NEUE. This indicates lower risk in terms of short-term price fluctuations for DSCI.Check NEUE's competition here
SANUWAVE Health Inc. (NASDAQ: SNWV)
DSCI vs SNWV Comparison August 2026
Derma Sciences, Inc. (NASDAQ: DSCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DSCI stands at 0. In comparison, SNWV has a market cap of 50.6M. Regarding current trading prices, DSCI is priced at $7.00 on the NASDAQ, while SNWV trades at $5.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DSCI currently has a P/E ratio of -0.02, whereas SNWV's P/E ratio is 17.82. In terms of profitability, DSCI's ROE is -0.00%, compared to SNWV's ROE of +17.28%. Regarding short-term risk, DSCI is less volatile compared to SNWV. This indicates lower risk in terms of short-term price fluctuations for DSCI.Check SNWV's competition here
Ekso Bionics Holdings, Inc. (NASDAQ: EKSO)
DSCI vs EKSO Comparison August 2026
Derma Sciences, Inc. (NASDAQ: DSCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DSCI stands at 0. In comparison, EKSO has a market cap of 38.6M. Regarding current trading prices, DSCI is priced at $7.00 on the NASDAQ, while EKSO trades at $15.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DSCI currently has a P/E ratio of -0.02, whereas EKSO's P/E ratio is -3.11. In terms of profitability, DSCI's ROE is -0.00%, compared to EKSO's ROE of -1.77%. Regarding short-term risk, DSCI is less volatile compared to EKSO. This indicates lower risk in terms of short-term price fluctuations for DSCI.Check EKSO's competition here
HeartBeam, Inc. (NASDAQ: BEAT)
DSCI vs BEAT Comparison August 2026
Derma Sciences, Inc. (NASDAQ: DSCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DSCI stands at 0. In comparison, BEAT has a market cap of 29.1M. Regarding current trading prices, DSCI is priced at $7.00 on the NASDAQ, while BEAT trades at $0.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DSCI currently has a P/E ratio of -0.02, whereas BEAT's P/E ratio is -0.94. In terms of profitability, DSCI's ROE is -0.00%, compared to BEAT's ROE of -10.34%. Regarding short-term risk, DSCI is less volatile compared to BEAT. This indicates lower risk in terms of short-term price fluctuations for DSCI.Check BEAT's competition here
Sharps Technology Inc. Wt (NASDAQ: STSSW)
DSCI vs STSSW Comparison August 2026
Derma Sciences, Inc. (NASDAQ: DSCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DSCI stands at 0. In comparison, STSSW has a market cap of 839.4K. Regarding current trading prices, DSCI is priced at $7.00 on the NASDAQ, while STSSW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DSCI currently has a P/E ratio of -0.02, whereas STSSW's P/E ratio is -0.03. In terms of profitability, DSCI's ROE is -0.00%, compared to STSSW's ROE of N/A. Regarding short-term risk, DSCI is more volatile compared to STSSW. This indicates higher risk in terms of short-term price fluctuations for DSCI.Check STSSW's competition here
Advisory Board Co. (The) (NASDAQ: ABCO)
DSCI vs ABCO Comparison August 2026
Derma Sciences, Inc. (NASDAQ: DSCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DSCI stands at 0. In comparison, ABCO has a market cap of 0. Regarding current trading prices, DSCI is priced at $7.00 on the NASDAQ, while ABCO trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DSCI currently has a P/E ratio of -0.02, whereas ABCO's P/E ratio is 0.52. In terms of profitability, DSCI's ROE is -0.00%, compared to ABCO's ROE of +0.19%. Regarding short-term risk, DSCI is more volatile compared to ABCO. This indicates higher risk in terms of short-term price fluctuations for DSCI.Check ABCO's competition here
Surgical Care Affiliates, Inc. (NASDAQ: SCAI)
DSCI vs SCAI Comparison August 2026
Derma Sciences, Inc. (NASDAQ: DSCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DSCI stands at 0. In comparison, SCAI has a market cap of 0. Regarding current trading prices, DSCI is priced at $7.00 on the NASDAQ, while SCAI trades at $55.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DSCI currently has a P/E ratio of -0.02, whereas SCAI's P/E ratio is 63.45. In terms of profitability, DSCI's ROE is -0.00%, compared to SCAI's ROE of +0.09%. Regarding short-term risk, DSCI is more volatile compared to SCAI. This indicates higher risk in terms of short-term price fluctuations for DSCI.Check SCAI's competition here
Landauer Inc. (NYSE: LDR)
DSCI vs LDR Comparison August 2026
Derma Sciences, Inc. (NASDAQ: DSCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DSCI stands at 0. In comparison, LDR has a market cap of 0. Regarding current trading prices, DSCI is priced at $7.00 on the NASDAQ, while LDR trades at $67.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DSCI currently has a P/E ratio of -0.02, whereas LDR's P/E ratio is N/A. In terms of profitability, DSCI's ROE is -0.00%, compared to LDR's ROE of +1.17%. Regarding short-term risk, DSCI is more volatile compared to LDR. This indicates higher risk in terms of short-term price fluctuations for DSCI.Check LDR's competition here
Mazor Robotics Ltd. (NASDAQ: MZOR)
DSCI vs MZOR Comparison August 2026
Derma Sciences, Inc. (NASDAQ: DSCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DSCI stands at 0. In comparison, MZOR has a market cap of 0. Regarding current trading prices, DSCI is priced at $7.00 on the NASDAQ, while MZOR trades at $58.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DSCI currently has a P/E ratio of -0.02, whereas MZOR's P/E ratio is -70.18. In terms of profitability, DSCI's ROE is -0.00%, compared to MZOR's ROE of -0.14%. Regarding short-term risk, DSCI is more volatile compared to MZOR. This indicates higher risk in terms of short-term price fluctuations for DSCI.Check MZOR's competition here
Med-Design Corp. (The) (NASDAQ: MEDC)
DSCI vs MEDC Comparison August 2026
Derma Sciences, Inc. (NASDAQ: DSCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DSCI stands at 0. In comparison, MEDC has a market cap of 0. Regarding current trading prices, DSCI is priced at $7.00 on the NASDAQ, while MEDC trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DSCI currently has a P/E ratio of -0.02, whereas MEDC's P/E ratio is N/A. In terms of profitability, DSCI's ROE is -0.00%, compared to MEDC's ROE of N/A. Regarding short-term risk, DSCI is less volatile compared to MEDC. This indicates lower risk in terms of short-term price fluctuations for DSCI.Check MEDC's competition here
St. Jude Medical, Inc. (NYSE: STJ)
DSCI vs STJ Comparison August 2026
Derma Sciences, Inc. (NASDAQ: DSCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DSCI stands at 0. In comparison, STJ has a market cap of 0. Regarding current trading prices, DSCI is priced at $7.00 on the NASDAQ, while STJ trades at $80.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DSCI currently has a P/E ratio of -0.02, whereas STJ's P/E ratio is 34.69. In terms of profitability, DSCI's ROE is -0.00%, compared to STJ's ROE of +0.21%. Regarding short-term risk, DSCI is more volatile compared to STJ. This indicates higher risk in terms of short-term price fluctuations for DSCI.Check STJ's competition here
LifePoint Health, Inc. (NASDAQ: LPNT)
DSCI vs LPNT Comparison August 2026
Derma Sciences, Inc. (NASDAQ: DSCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DSCI stands at 0. In comparison, LPNT has a market cap of 0. Regarding current trading prices, DSCI is priced at $7.00 on the NASDAQ, while LPNT trades at $64.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DSCI currently has a P/E ratio of -0.02, whereas LPNT's P/E ratio is 67.44. In terms of profitability, DSCI's ROE is -0.00%, compared to LPNT's ROE of +0.05%. Regarding short-term risk, DSCI is more volatile compared to LPNT. This indicates higher risk in terms of short-term price fluctuations for DSCI.Check LPNT's competition here
Cynosure, Inc. (NASDAQ: CYNO)
DSCI vs CYNO Comparison August 2026
Derma Sciences, Inc. (NASDAQ: DSCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DSCI stands at 0. In comparison, CYNO has a market cap of 0. Regarding current trading prices, DSCI is priced at $7.00 on the NASDAQ, while CYNO trades at $66.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DSCI currently has a P/E ratio of -0.02, whereas CYNO's P/E ratio is 105.35. In terms of profitability, DSCI's ROE is -0.00%, compared to CYNO's ROE of +0.03%. Regarding short-term risk, DSCI is more volatile compared to CYNO. This indicates higher risk in terms of short-term price fluctuations for DSCI.Check CYNO's competition here
Pharmerica Corporation (NYSE: PMC)
DSCI vs PMC Comparison August 2026
Derma Sciences, Inc. (NASDAQ: DSCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DSCI stands at 0. In comparison, PMC has a market cap of 0. Regarding current trading prices, DSCI is priced at $7.00 on the NASDAQ, while PMC trades at $29.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DSCI currently has a P/E ratio of -0.02, whereas PMC's P/E ratio is 47.95. In terms of profitability, DSCI's ROE is -0.00%, compared to PMC's ROE of +0.04%. Regarding short-term risk, DSCI is more volatile compared to PMC. This indicates higher risk in terms of short-term price fluctuations for DSCI.Check PMC's competition here
Abaxis, Inc. (NASDAQ: ABAX)
DSCI vs ABAX Comparison August 2026
Derma Sciences, Inc. (NASDAQ: DSCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DSCI stands at 0. In comparison, ABAX has a market cap of 0. Regarding current trading prices, DSCI is priced at $7.00 on the NASDAQ, while ABAX trades at $83.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DSCI currently has a P/E ratio of -0.02, whereas ABAX's P/E ratio is 70.62. In terms of profitability, DSCI's ROE is -0.00%, compared to ABAX's ROE of +0.10%. Regarding short-term risk, DSCI is more volatile compared to ABAX. This indicates higher risk in terms of short-term price fluctuations for DSCI.Check ABAX's competition here
Envision Healthcare Corporation (NYSE: EVHC)
DSCI vs EVHC Comparison August 2026
Derma Sciences, Inc. (NASDAQ: DSCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DSCI stands at 0. In comparison, EVHC has a market cap of 0. Regarding current trading prices, DSCI is priced at $7.00 on the NASDAQ, while EVHC trades at $45.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DSCI currently has a P/E ratio of -0.02, whereas EVHC's P/E ratio is -3.20. In terms of profitability, DSCI's ROE is -0.00%, compared to EVHC's ROE of +0.07%. Regarding short-term risk, DSCI is more volatile compared to EVHC. This indicates higher risk in terms of short-term price fluctuations for DSCI.Check EVHC's competition here
Cotiviti Holdings, Inc. (NYSE: COTV)
DSCI vs COTV Comparison August 2026
Derma Sciences, Inc. (NASDAQ: DSCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DSCI stands at 0. In comparison, COTV has a market cap of 0. Regarding current trading prices, DSCI is priced at $7.00 on the NASDAQ, while COTV trades at $44.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DSCI currently has a P/E ratio of -0.02, whereas COTV's P/E ratio is 26.51. In terms of profitability, DSCI's ROE is -0.00%, compared to COTV's ROE of +0.14%. Regarding short-term risk, DSCI is more volatile compared to COTV. This indicates higher risk in terms of short-term price fluctuations for DSCI.Check COTV's competition here
AmSurg Corp (NASDAQ: AMSG)
DSCI vs AMSG Comparison August 2026
Derma Sciences, Inc. (NASDAQ: DSCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DSCI stands at 0. In comparison, AMSG has a market cap of 0. Regarding current trading prices, DSCI is priced at $7.00 on the NASDAQ, while AMSG trades at $67.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DSCI currently has a P/E ratio of -0.02, whereas AMSG's P/E ratio is N/A. In terms of profitability, DSCI's ROE is -0.00%, compared to AMSG's ROE of +0.08%. Regarding short-term risk, DSCI is less volatile compared to AMSG. This indicates lower risk in terms of short-term price fluctuations for DSCI.Check AMSG's competition here
Spectranetics Corp. (The) (NASDAQ: SPNC)
DSCI vs SPNC Comparison August 2026
Derma Sciences, Inc. (NASDAQ: DSCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DSCI stands at 0. In comparison, SPNC has a market cap of 0. Regarding current trading prices, DSCI is priced at $7.00 on the NASDAQ, while SPNC trades at $38.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DSCI currently has a P/E ratio of -0.02, whereas SPNC's P/E ratio is -24.03. In terms of profitability, DSCI's ROE is -0.00%, compared to SPNC's ROE of -0.61%. Regarding short-term risk, DSCI is more volatile compared to SPNC. This indicates higher risk in terms of short-term price fluctuations for DSCI.Check SPNC's competition here
Span-America Medical Systems, Inc. (NASDAQ: SPAN)
DSCI vs SPAN Comparison August 2026
Derma Sciences, Inc. (NASDAQ: DSCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DSCI stands at 0. In comparison, SPAN has a market cap of 0. Regarding current trading prices, DSCI is priced at $7.00 on the NASDAQ, while SPAN trades at $29.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DSCI currently has a P/E ratio of -0.02, whereas SPAN's P/E ratio is N/A. In terms of profitability, DSCI's ROE is -0.00%, compared to SPAN's ROE of +0.17%. Regarding short-term risk, DSCI is less volatile compared to SPAN. This indicates lower risk in terms of short-term price fluctuations for DSCI.Check SPAN's competition here
Exactech, Inc. (NASDAQ: EXAC)
DSCI vs EXAC Comparison August 2026
Derma Sciences, Inc. (NASDAQ: DSCI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DSCI stands at 0. In comparison, EXAC has a market cap of 0. Regarding current trading prices, DSCI is priced at $7.00 on the NASDAQ, while EXAC trades at $49.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DSCI currently has a P/E ratio of -0.02, whereas EXAC's P/E ratio is 3510.33. In terms of profitability, DSCI's ROE is -0.00%, compared to EXAC's ROE of +0.00%. Regarding short-term risk, DSCI is more volatile compared to EXAC. This indicates higher risk in terms of short-term price fluctuations for DSCI.Check EXAC's competition here